Appili Therapeutics Inc (APLI : TSX)
Common Stock
$0.01
CAD
+0.00 (%)
Last updated: 2026-07-07
APLI
Appili Therapeutics Inc
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+0.00%
1 Month
+0.00%
YTD
-40.00%
Key Statistics
Market Cap
$1.99M
52W High
$0.04
52W Low
$0.01
P/E Ratio
-
50 Day MA
$0.02
200 Day MA
$0.02
Beta
-0.21
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/7/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 64,000 |
| 7/3/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 7/2/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 58,300 |
| 6/30/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 25,000 |
| 6/29/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 37,010 |
| 6/26/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 6/25/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 1,000 |
| 6/24/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 6/23/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
| 6/22/2026 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 0 |
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 900.0% over the next 12 months.
Consensus
No RatingAvg. Target
C$0.15
+900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
169.6%
Annualized
90-Day Vol
206.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.01 โ C$0.03 |
| 60 trading days | C$0.01 | C$0.01 โ C$0.03 |
| 90 trading days | C$0.01 | C$0.00 โ C$0.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Financials
- Revenue (TTM)
- $244,179
- EBITDA
- $-6.52M
- Profit Margin
- 0.00%
- ROE (TTM)
- -938.72%
- EPS (Diluted)
- -0.03
- Book Value
- -0.13
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About APLI
Articles Featuring APLI.TO
Latest articles and analysis covering APLI.TO
